Price movement over the last 24 hours
ACM Research Inc vs Twist Bioscience Corp — how do they compare? ACM Research Inc trades at $95.74 (market cap $6.54B), while Twist Bioscience Corp trades at $89.05 (market cap $5.67B). The key difference: ACM Research Inc is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, ACM Research Inc nearer its low. Which is the better fit depends on your goals.
| ACMR | TWST | |
|---|---|---|
Market Cap | $6.54B | $5.67B |
Sector | Technology | Health |
52-Week High | $126.89 | $102.88 |
52-Week Low | $23.92 | $24.16 |
Enterprise Value | $5.61B | $5.59B |
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).
Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.
Twist Bioscience (TWST) trades at $91.03, down 8.27% in the past day, amid mixed earnings performance. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Revenue growth remains robust, rising to $377 million in 2025, but profitability challenges persist with a net income margin of -19.85%. Recent news highlights AI-driven drug discovery collaborations and insider selling activity.
The outlook is cautiously optimistic given analyst consensus favoring buys (76.93%) and a price target near current levels. Key risks include sustained cash burn, competitive pressures in synthetic biology, and execution on path to profitability. Upside hinges on revenue acceleration and margin improvement from new product launches and AI partnerships.
Trailing returns across standard periods
Latest headlines on both assets
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →